Sarepta (SRPT) — pipeline, SEC filings & news

Pipeline — registered trials by phase

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

— · Duchenne Muscular Dystrophy · Active Not Recruiting · est. 2027-05-31

Study of Eteplirsen in DMD Patients

— · Duchenne Muscular Dystrophy (DMD) · Completed · est. 2019-06-14

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

— · Muscular Dystrophy, Duchenne · Active Not Recruiting · est. 2026-10-31

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

— · Duchenne Muscular Dystrophy · Completed · est. 2024-11-12

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

— · Limb-girdle Muscular Dystrophy · Active Not Recruiting · est. 2025-03-04

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

— · Duchenne Muscular Dystrophy · Enrolling By Invitation · est. 2033-10-31

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

— · Duchenne Muscular Dystrophy · Completed · est. 2023-10-04

Source: ClinicalTrials.gov (trials where Sarepta is lead sponsor; 36 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.

SEC filings — insider trading forms excluded

8-K2026-09-23Current report (material event)
13F-HR2026-08-1413F-HR
SCHEDULE 13G/A2026-08-13SCHEDULE 13G/A
SCHEDULE 13G2026-08-07SCHEDULE 13G
8-K2026-08-05Current report (material event)
10-Q2026-08-05Quarterly report
SCHEDULE 13G/A2026-07-31SCHEDULE 13G/A
SCHEDULE 13G/A2026-07-30SCHEDULE 13G/A
S-82026-07-28Employee stock plan
8-K2026-07-27Current report (material event)
S-82026-06-04Employee stock plan
8-K2026-06-04Current report (material event)
13F-HR2026-05-1313F-HR
8-K2026-05-06Current report (material event)
10-Q2026-05-06Quarterly report
SCHEDULE 13G2026-04-30SCHEDULE 13G
SCHEDULE 13G2026-04-29SCHEDULE 13G
ARS2026-04-24Annual report to holders
DEFA14A2026-04-24DEFA14A
DEF 14A2026-04-24Proxy statement
SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
10-K2026-03-02Annual report
8-K2026-02-25Current report (material event)
8-K2026-02-25Current report (material event)
SCHEDULE 13G2026-02-13SCHEDULE 13G
13F-HR2026-02-1313F-HR
SCHEDULE 13G/A2026-01-21SCHEDULE 13G/A
8-K2026-01-12Current report (material event)
8-K2025-12-19Current report (material event)
8-K2025-12-11Current report (material event)
8-K2025-12-08Current report (material event)
SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
SCHEDULE 13G2025-11-10SCHEDULE 13G
10-Q2025-11-06Quarterly report
8-K2025-11-03Current report (material event)
SCHEDULE 13G/A2025-09-08SCHEDULE 13G/A
8-K2025-08-29Current report (material event)
8-K2025-08-21Current report (material event)
SCHEDULE 13D/A2025-08-15SCHEDULE 13D/A
8-K2025-08-13Current report (material event)

Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.

Sarepta SRPT

Pipeline — registered trials by phase

SEC filings — insider trading forms excluded